Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Apterna Limited is dealing with 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being reviewed by 1 distinct examiner, POLIAKOVA-GEORGAN, EKATERINA, who holds the 1 busiest examiner pending office action. The prosecution activity is restricted to 1 distinct art unit, indicating a narrow technical focus for the current pending application. This allows for a precise and targeted response to the 1 pending office action currently in the queue.
The presence of 1 pending office action means the practitioner can dedicate their attention to the specific feedback of 1 distinct examiner. There is no complexity arising from multiple examiners or different art units. By concentrating on 1 distinct art unit, the applicant can ensure their arguments are aligned with the specific technical standards of that unit. This focused prosecution environment minimizes the risk of conflicting examiner requirements. The legal team can focus on the 1 busiest examiner pending office action to move the portfolio toward allowance without the distraction of broader administrative management.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| POLIAKOVA-GEORGAN, EKATERINA | 1 | 64.0% | +18.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18256707 | APTAMER-siRNA FUSIONS | POLIAKOVA-GEORGAN, EKATERINA | 28d |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18256707 | APTAMER-siRNA FUSIONS | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §103Other | Non-Final OA | 28d | Pending | Jun 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial